NCT04761653Unknown不适用
Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas
Central Hospital, Nancy, France1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2021年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy.
This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208).
This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •primary diagnosis of atypical meningioma
排除标准
- 未提供
结局指标
主要结局
Progression free survival
时间窗: 2-21 years
次要结局
- Overall survival(2-21 years)
研究者
Guillaume GAUCHOTTE
PU PH
Central Hospital, Nancy, France
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Role of the Tumor Microenvironment in Aggressive MeningiomasMeningiomaNCT05821790Assistance Publique - Hôpitaux de Paris40
已完成
不适用
Characterization and Differential Diagnosis of Postneurosurgical MeningitisNeurosurgeryNCT01122537Asan Medical Center78
招募中
1 期
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotideMeningiomaNCT04997317University Hospital, Basel, Switzerland18
招募中
2 期
177Lu-DOTATATE for Recurrent MeningiomaRecurrent MeningiomaNCT06326190European Organisation for Research and Treatment of Cancer - EORTC136
招募中
不适用
Embolization for MeningiomaMeningiomaNCT05416567St. Olavs Hospital30